GRK4 Polymorphisms Blood Pressure Response to Candesartan
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
- The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension [ Time Frame: two years ] [ Designated as safety issue: Yes ]
|Study Start Date:||July 2013|
|Estimated Study Completion Date:||July 2015|
|Estimated Primary Completion Date:||July 2015 (Final data collection date for primary outcome measure)|
No Intervention: candesartan
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Other Name: GRK4 polymorphisms and essential hypertrension
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01629225
|Contact: Yu changqing, Doctorfirstname.lastname@example.org|
|Department of Cardiology, Daping Hospital, The Third Military Medical University||Recruiting|
|Chongqing, China, 400042|
|Contact: Yu Changqing, MD email@example.com|
|Study Director:||Zeng Chunyu, Doctor||TMMU|